

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging therapies in the management of macular... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1413/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1413" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging therapies in the management of macular edema: a review" />
    
            <meta name="og:title" content="F1000Research Article: Emerging therapies in the management of macular edema: a review.">
            <meta name="og:description" content="Read the latest article version by Riccardo Sacconi, Chiara Giuffr&egrave;, Eleonora Corbelli, Enrico Borrelli, Giuseppe Querques, Francesco Bandello, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21038">
            <meta name="article-id" content="19198">
            <meta name="dc.title" content="Emerging therapies in the management of macular edema: a review">
            <meta name="dc.description" content="Macular edema (ME) is a major complication of several vascular and inflammatory retinal diseases. Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). For this reason, an effective approach to the treatment of ME is of paramount importance in order to prevent irreversible damage of visual function. In this review, we discuss the management of ME and, in particular, current data of studies and clinical trials about drugs that have already been evaluated or are under investigation in the management of ME. Although several diseases could lead to the development of ME, we focus on the three main causes: diabetic retinopathy (DR), retinal vein occlusion (RVO), and uveitis. The introduction into clinical practice of anti-vascular endothelial growth factor injections (ranibizumab and aflibercept) and dexamethasone implants has revolutionized the treatment of ME secondary to DR and RVO. However, new drugs are needed in the treatment of resistant forms of ME secondary to DR and RVO. A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO. Furthermore, brolucizumab and abicipar pegol have been shown to be effective in preliminary studies and have the chance to be approved soon for diabetic ME treatment. In ME secondary to uveitis, a crucial role is played by corticosteroids and non-biologic immunomodulatory drugs. However, several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy. However, only a few of these drugs will enter the market after proving their safety and efficacy. Only after that will we be able to offer a new therapeutic option to patients affected by uveitic ME.">
            <meta name="dc.subject" content="corticosteroid, diabetic macular edema, macular edema, retinal vein occlusion, uveitic macular edema, uveitis, vascular endothelial growth factor">
            <meta name="dc.creator" content="Sacconi, Riccardo">
            <meta name="dc.creator" content="Giuffr&egrave;, Chiara">
            <meta name="dc.creator" content="Corbelli, Eleonora">
            <meta name="dc.creator" content="Borrelli, Enrico">
            <meta name="dc.creator" content="Querques, Giuseppe">
            <meta name="dc.creator" content="Bandello, Francesco">
            <meta name="dc.date" content="2019/08/12">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19198.1">
            <meta name="dc.source" content="F1000Research 2019 8:1413">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="corticosteroid">
            <meta name="prism.keyword" content="diabetic macular edema">
            <meta name="prism.keyword" content="macular edema">
            <meta name="prism.keyword" content="retinal vein occlusion">
            <meta name="prism.keyword" content="uveitic macular edema">
            <meta name="prism.keyword" content="uveitis">
            <meta name="prism.keyword" content="vascular endothelial growth factor">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/08/12">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1413">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19198.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1413">
            <meta name="citation_title" content="Emerging therapies in the management of macular edema: a review">
            <meta name="citation_abstract" content="Macular edema (ME) is a major complication of several vascular and inflammatory retinal diseases. Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). For this reason, an effective approach to the treatment of ME is of paramount importance in order to prevent irreversible damage of visual function. In this review, we discuss the management of ME and, in particular, current data of studies and clinical trials about drugs that have already been evaluated or are under investigation in the management of ME. Although several diseases could lead to the development of ME, we focus on the three main causes: diabetic retinopathy (DR), retinal vein occlusion (RVO), and uveitis. The introduction into clinical practice of anti-vascular endothelial growth factor injections (ranibizumab and aflibercept) and dexamethasone implants has revolutionized the treatment of ME secondary to DR and RVO. However, new drugs are needed in the treatment of resistant forms of ME secondary to DR and RVO. A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO. Furthermore, brolucizumab and abicipar pegol have been shown to be effective in preliminary studies and have the chance to be approved soon for diabetic ME treatment. In ME secondary to uveitis, a crucial role is played by corticosteroids and non-biologic immunomodulatory drugs. However, several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy. However, only a few of these drugs will enter the market after proving their safety and efficacy. Only after that will we be able to offer a new therapeutic option to patients affected by uveitic ME.">
            <meta name="citation_description" content="Macular edema (ME) is a major complication of several vascular and inflammatory retinal diseases. Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). For this reason, an effective approach to the treatment of ME is of paramount importance in order to prevent irreversible damage of visual function. In this review, we discuss the management of ME and, in particular, current data of studies and clinical trials about drugs that have already been evaluated or are under investigation in the management of ME. Although several diseases could lead to the development of ME, we focus on the three main causes: diabetic retinopathy (DR), retinal vein occlusion (RVO), and uveitis. The introduction into clinical practice of anti-vascular endothelial growth factor injections (ranibizumab and aflibercept) and dexamethasone implants has revolutionized the treatment of ME secondary to DR and RVO. However, new drugs are needed in the treatment of resistant forms of ME secondary to DR and RVO. A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO. Furthermore, brolucizumab and abicipar pegol have been shown to be effective in preliminary studies and have the chance to be approved soon for diabetic ME treatment. In ME secondary to uveitis, a crucial role is played by corticosteroids and non-biologic immunomodulatory drugs. However, several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy. However, only a few of these drugs will enter the market after proving their safety and efficacy. Only after that will we be able to offer a new therapeutic option to patients affected by uveitic ME.">
            <meta name="citation_keywords" content="corticosteroid, diabetic macular edema, macular edema, retinal vein occlusion, uveitic macular edema, uveitis, vascular endothelial growth factor">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Riccardo Sacconi">
            <meta name="citation_author_institution" content="Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy">
            <meta name="citation_author" content="Chiara Giuffr&egrave;">
            <meta name="citation_author_institution" content="Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy">
            <meta name="citation_author" content="Eleonora Corbelli">
            <meta name="citation_author_institution" content="Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy">
            <meta name="citation_author" content="Enrico Borrelli">
            <meta name="citation_author_institution" content="Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy">
            <meta name="citation_author" content="Giuseppe Querques">
            <meta name="citation_author_institution" content="Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy">
            <meta name="citation_author" content="Francesco Bandello">
            <meta name="citation_author_institution" content="Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy">
            <meta name="citation_publication_date" content="2019/08/12">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1413">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19198.1">
            <meta name="citation_firstpage" content="1413">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1413/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1413.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21038 /> <input type=hidden id=articleId name=articleId value=19198 /> <input type=hidden id=xmlUrl value="/articles/8-1413/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1413-v1.xml"> <input type=hidden id=article_uuid value=c54108b9-ee0c-4585-b5b0-59751df96f8b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging therapies in the management of macular edema: a review"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19198.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19198.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1413"
  },
  "headline": "Emerging therapies in the management of macular edema: a review",
  "datePublished": "2019-08-12T09:21:30",
  "dateModified": "2019-08-12T09:21:30",
  "author": [
    {
      "@type": "Person",
      "name": "Riccardo Sacconi"
    },    {
      "@type": "Person",
      "name": "Chiara Giuffr&egrave;"
    },    {
      "@type": "Person",
      "name": "Eleonora Corbelli"
    },    {
      "@type": "Person",
      "name": "Enrico Borrelli"
    },    {
      "@type": "Person",
      "name": "Giuseppe Querques"
    },    {
      "@type": "Person",
      "name": "Francesco Bandello"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Macular edema (ME) is a major complication of several vascular and inflammatory retinal diseases. Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). For this reason, an effective approach to the treatment of ME is of paramount importance in order to prevent irreversible damage of visual function. In this review, we discuss the management of ME and, in particular, current data of studies and clinical trials about drugs that have already been evaluated or are under investigation in the management of ME. Although several diseases could lead to the development of ME, we focus on the three main causes: diabetic retinopathy (DR), retinal vein occlusion (RVO), and uveitis. The introduction into clinical practice of anti-vascular endothelial growth factor injections (ranibizumab and aflibercept) and dexamethasone implants has revolutionized the treatment of ME secondary to DR and RVO. However, new drugs are needed in the treatment of resistant forms of ME secondary to DR and RVO. A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO. Furthermore, brolucizumab and abicipar pegol have been shown to be effective in preliminary studies and have the chance to be approved soon for diabetic ME treatment. In ME secondary to uveitis, a crucial role is played by corticosteroids and non-biologic immunomodulatory drugs. However, several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy. However, only a few of these drugs will enter the market after proving their safety and efficacy. Only after that will we be able to offer a new therapeutic option to patients affected by uveitic ME."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1413/v1",
            "name": "Emerging therapies in the management of macular edema: a review"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging therapies in the management of macular edema: a review </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21038 data-id=19198 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19198.1" data-recommended="" data-doi="10.12688/f1000research.19198.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1413/v1/pdf?article_uuid=c54108b9-ee0c-4585-b5b0-59751df96f8b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19198-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19198-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19198-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Sacconi R, Giuffr C, Corbelli E <em>et al.</em> Emerging therapies in the management of macular edema: a review [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1413 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19198.1" target=_blank>https://doi.org/10.12688/f1000research.19198.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19198-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19198 id=track-article-signin-19198 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19198?target=/articles/8-1413/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21038 /> <input name=articleId type=hidden value=19198 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging therapies in the management of macular edema: a review</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Riccardo Sacconi,&nbsp;</span><span class="">Chiara Giuffr&egrave;,&nbsp;</span><span class="">Eleonora Corbelli,&nbsp;</span><span class="">Enrico Borrelli,&nbsp;</span><span class="">Giuseppe Querques,&nbsp;</span><span class=""><a href="mailto:bandello.francesco@hsr.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Francesco Bandello</span></a><a href="https://orcid.org/0000-0003-3238-9682" target=_blank id=author-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3238-9682</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Riccardo Sacconi,&nbsp;</span><span class="">Chiara Giuffr&egrave;,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Eleonora Corbelli,&nbsp;</span><span class=article-page-hidden-authors>Enrico Borrelli,&nbsp;</span><span class="">Giuseppe Querques,&nbsp;</span><span class=""><a href="mailto:bandello.francesco@hsr.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Francesco Bandello</span></a><a href="http://orcid.org/0000-0003-3238-9682" target=_blank id=mauthor-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-3238-9682</div></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 12 Aug 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19198.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy<br/> <p> <div class=margin-bottom> Riccardo Sacconi <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Resources, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Chiara Giuffr&egrave; <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Eleonora Corbelli <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Enrico Borrelli <br/> <span>Roles: </span> Data Curation, Methodology, Resources, Validation, Writing  Review & Editing </div> <div class=margin-bottom> Giuseppe Querques <br/> <span>Roles: </span> Conceptualization, Methodology, Resources, Validation, Writing  Review & Editing </div> <div class=margin-bottom> Francesco Bandello <br/> <span>Roles: </span> Conceptualization, Methodology, Resources, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=54919-51943></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=54920-51942></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Macular edema (ME) is a major complication of several vascular and inflammatory retinal diseases. Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). For this reason, an effective approach to the treatment of ME is of paramount importance in order to prevent irreversible damage of visual function. In this review, we discuss the management of ME and, in particular, current data of studies and clinical trials about drugs that have already been evaluated or are under investigation in the management of ME. Although several diseases could lead to the development of ME, we focus on the three main causes: diabetic retinopathy (DR), retinal vein occlusion (RVO), and uveitis. The introduction into clinical practice of anti-vascular endothelial growth factor injections (ranibizumab and aflibercept) and dexamethasone implants has revolutionized the treatment of ME secondary to DR and RVO. However, new drugs are needed in the treatment of resistant forms of ME secondary to DR and RVO. A fluocinolone acetonide implant has been approved by the US Food and Drug Administration for the treatment of diabetic ME but not for RVO. Furthermore, brolucizumab and abicipar pegol have been shown to be effective in preliminary studies and have the chance to be approved soon for diabetic ME treatment. In ME secondary to uveitis, a crucial role is played by corticosteroids and non-biologic immunomodulatory drugs. However, several new biologic agents are under investigation in different clinical trials and could be important new therapeutic options in cases with a low response to first-line therapy. However, only a few of these drugs will enter the market after proving their safety and efficacy. Only after that will we be able to offer a new therapeutic option to patients affected by uveitic ME. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> corticosteroid, diabetic macular edema, macular edema, retinal vein occlusion, uveitic macular edema, uveitis, vascular endothelial growth factor </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Francesco Bandello (<a href="mailto:bandello.francesco@hsr.it">bandello.francesco@hsr.it</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Francesco Bandello </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> GQ is a consultant for Alimera Sciences, Allergan Inc., Amgen (Thousand Oaks, CA, USA), Bayer Schering-Pharma (Berlin, Germany), Heidelberg (Germany), KBH (Chengdu; China), LEH Pharma (London, UK), LumiThera (Poulsbo, WA, USA), Novartis (Basel, Switzerland), Sandoz (Berlin, Germany), Sifi (Catania, Italy), Sooft-Fidea (Abano, Italy), and Zeiss (Dublin, OH, USA). FB is a consultant for Alcon (Fort Worth, TX, USA), Alimera Sciences, Allergan Inc., Farmila-Thea (Clermont-Ferrand, France), Bayer Schering-Pharma, Bausch + Lomb, Genentech, Hoffmann-La Roche (Basel, Switzerland), Novagali Pharma (vry, France), Novartis, Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), and Zeiss. The other authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2019 Sacconi R <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Sacconi R, Giuffr C, Corbelli E <em>et al.</em> Emerging therapies in the management of macular edema: a review [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1413 (<a href="https://doi.org/10.12688/f1000research.19198.1" target=_blank>https://doi.org/10.12688/f1000research.19198.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 12 Aug 2019, <b>8</b>(F1000 Faculty Rev):1413 (<a href="https://doi.org/10.12688/f1000research.19198.1" target=_blank>https://doi.org/10.12688/f1000research.19198.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 12 Aug 2019, <b>8</b>(F1000 Faculty Rev):1413 (<a href="https://doi.org/10.12688/f1000research.19198.1" target=_blank>https://doi.org/10.12688/f1000research.19198.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d33664e216>Introduction</h2><p class="" id=d33664e219>Macular edema (ME) is the major cause of visual impairment in several metabolic, vascular, and inflammatory retinal diseases. It affects about 7 million patients with diabetic retinopathy (DR)<sup><a href="#ref-1">1</a></sup> and 3 million patients with retinal vein occlusion (RVO)<sup><a href="#ref-2">2</a></sup> and causes a visual decline in 40% of patients affected by uveitis<sup><a href="#ref-3">3</a></sup>. ME is characterized by an abnormal presence of fluid inside the retinal layers of the macula<sup><a href="#ref-4">4</a></sup>. Normally, there is a fine balance between fluid that enters and exits inside the retinal layers. This balance is necessary for the retinal homeostasis in order to obtain the tissue transparency. However, for several diseases, this balance could be compromised, resulting in an imbalance between fluid that enters and exits and thus causing ME development. The accumulation of the fluid could be extracellular (resulting in cystic space formation), intracellular (causing a swelling of the cells), or subretinal (causing the accumulation in the subretinal space)<sup><a href="#ref-4">4</a><a href="#ref-6">6</a></sup>. The regulation of fluid and molecules that enter and exit from the vitreous, retinal vessels, and choroidal vessels is controlled by structures forming the inner and the outer blood-retinal barriers<sup><a href="#ref-7">7</a>,<a href="#ref-8">8</a></sup>. The inner blood-retinal barrier is composed of the tight junctions between the endothelial cells of the capillaries inside the retinal plexuses, astrocytes, Mller cells, pericytes, and smooth muscle cells<sup><a href="#ref-9">9</a><a href="#ref-11">11</a></sup>. On the other hand, the outer blood-retinal barrier is composed of the retinal pigment epithelium (RPE) cells and their inter-cellular junctions that regulate the passage of fluid and molecules from the choroidal vessels to the neurosensory retina<sup><a href="#ref-12">12</a></sup>.</p><p class="" id=d33664e264>ME causes visual impairment that could be reversible or permanent. Multiple mechanisms are implicated in the development of visual impairment due to ME. During the acute phase of ME development, the imbalance of fluid that enters and exits inside the retinal layers causes a retinal hydration state that interferes with the passage of light through the neuroretinal layers. These alterations lead to an acute effect on visual function, such as central vision loss, a relative central scotoma, metamorphopsia, impaired stereopsis, or disturbed color vision<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. In this phase, the treatment or the spontaneous resolution of ME is able to reverse the visual impairment. On the other hand, long-standing ME causes irreversible changes of the retinal layers, leading to a permanent deficit in visual function. The main anatomical damage caused by chronic ME is linked to alterations of the outer limiting membrane, photoreceptor segments (outer nuclear layer thinning and outer segment atrophy), and disorganization of inner retinal layers<sup><a href="#ref-15">15</a><a href="#ref-17">17</a></sup>. For these reasons, the treatment of ME should be performed as soon as possible in order to avoid structural retinal changes and irreversible damage of visual function.</p><p class="" id=d33664e281>In this review, we focus on the management of ME and, in particular, on current data of studies and clinical trials about drugs that are under investigation or have already been evaluated in ME management. Although several diseases could lead to the development of ME (that is, DR<sup><a href="#ref-1">1</a></sup>, RVO<sup><a href="#ref-2">2</a></sup>, uveitis<sup><a href="#ref-3">3</a></sup>, IrvineGass postoperative ME<sup><a href="#ref-18">18</a></sup>, idiopathic macular telangiectasia type 1 and 2<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>, perifoveal exudative vascular anomalous complex<sup><a href="#ref-21">21</a></sup>, paclitaxel-induced maculopathy<sup><a href="#ref-22">22</a></sup>, MEK inhibitorassociated maculopathy<sup><a href="#ref-23">23</a></sup>, hypoproteinemia<sup><a href="#ref-24">24</a></sup>, paracentral acute middle maculopathy<sup><a href="#ref-25">25</a></sup>, and central serous chorioretinopathy<sup><a href="#ref-26">26</a></sup>), we will discuss the management of the major causes of ME, including DR, RVO, and uveitis.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33664e335>Management of macular edema: diabetic retinopathy</h2><p class="" id=d33664e338>Diabetic macular edema (DME) is the first cause of visual loss in patients with diabetes<sup><a href="#ref-27">27</a></sup>. For several years, grid and focal laser photocoagulation were considered the standard of care for DME. However, thanks to the introduction into clinical practice of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections and corticosteroid implants, the treatment of DME has been completely revolutionized. Anti-VEGF molecules, such as ranibizumab (Lucentis, Novartis Europharm Ltd, Horsham, UK) and aflibercept (Eylea<sup></sup>, Bayer Pharma, Berlin, Germany), demonstrated a benefit ratio and superior efficacy compared with the previous standard of care (laser photocoagulation) in large phase 3 clinical trials<sup><a href="#ref-28">28</a><a href="#ref-32">32</a></sup>. The encouraging results in terms of clinically relevant improvement of visual acuity, reduction of fluid accumulation, and decreased severity of DR led to their approval for DME treatment by the US Food and Drug Administration (FDA) starting in 2012. Owing to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Besides ranibizumab and aflibercept, bevacizumab demonstrated efficacy in the treatment of DME. Bevacizumab is a monoclonal antibody used to treat a number of types of cancer, although its intraocular use is considered off-label. The Diabetic Retinopathy Clinical Research Network (DRCR.net) evaluated the outcomes of patients with DME treated with bevacizumab, ranibizumab, or aflibercept and reported best outcomes in patients whose DME was treated with aflibercept with visual acuity of 20/50 or worse at baseline<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d33664e359>Ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ, USA/Regeneron Pharmaceuticals, Tarrytown, NY, USA) is a fusion protein approved by the FDA for the treatment of metastatic colorectal carcinoma. Although aflibercept and ziv-aflibercept are structurally identical, they differ for the buffer. This difference results in a higher osmolarity of ziv-aflibercept compared to aflibercept. De Andrade <i>et al</i>.<sup><a href="#ref-34">34</a></sup> tested the safety and efficacy of ziv-aflibercept in seven eyes affected by DME and disclosed no systemic or ocular complications during a 48-week follow-up. Furthermore, Mansour <i>et al</i>.<sup><a href="#ref-35">35</a></sup> reported the off-label intraocular use of ziv-aflibercept in the treatment of 107 eyes affected by retinal diseases and concluded that ziv-aflibercept appeared safe and efficacious. However, further randomized studies are needed to demonstrate the safety and efficacy of intraocular use of ziv-aflibercept.</p><p class="" id=d33664e376>Corticosteroid implants are usually used as a second-line treatment for patients without significant response to anti-VEGF injections. In 2014, an intravitreal implant with 700 g of sustained-release biodegradable dexamethasone (Ozurdex<sup></sup>, Allergan, Inc., Irvine, CA, USA) was approved by the FDA for the treatment of DME. The MEAD study demonstrated the efficacy of dexamethasone implant in the treatment of DME with an acceptable safety profile and a low number of implants (four or five injections over a 3-year follow-up)<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d33664e386>Despite the strong efficacy achieved with anti-VEGF and corticosteroid therapies, a significant proportion of patients do not experience clinically meaningful improvements in vision in the real world with persistent or resistant forms of DME<sup><a href="#ref-37">37</a><a href="#ref-39">39</a></sup>. Moreover, frequent intravitreal administration is required to achieve and, in some cases, to maintain the observed early benefits of DME treatment over a long period of time, imposing a significant burden on patients, caregivers, treating physicians, and the health-care system. Both of these factors formed the impetus for developing new drugs and alternative methods of administration for the treatment of DME.</p><p class="" id=d33664e397>Novel treatment strategies for DME could be classified into four subgroups: a new slow-release sustained-delivery system for intraocular steroid, next-generation anti-VEGF-A drugs, combination drugs, and suprachoroidal corticosteroids.</p><div class=section><a name=d33664e400 class=n-a></a><h3 class=section-title>New slow-release sustained-delivery system for intraocular steroid</h3><p class="" id=d33664e405><b><i>Iluvien.</i></b> Iluvien (Alimera Sciences, Alpharetta, GA, USA) is an injectable non-biodegradable intravitreal insert for sustained release of fluocinolone acetonide (FAc), a potent glucocorticoid receptor agonist, for up to 36 months. The implant, inserted into the vitreous cavity via a 25-gauge needle, contains 0.19 mg of FAc and provides a release rate of 0.2 g/day. Iluvien is usually used for the treatment of DME in patients who previously received a course of corticosteroids and did not have a significant increase in eye pressure. The clinical efficacy of Iluvien has been evaluated in a phase 3 FAME clinical trial and confirmed by several real-life reports<sup><a href="#ref-40">40</a><a href="#ref-42">42</a></sup>. Of note, the continuous dosing ensures the treatment even in the case of delay to follow-up appointments. This is a fundamental advantage given that many factors can change the intensive dosing schedule required for optimal results in anti-VEGF therapy. Currently, Iluvien is approved by the FDA for the treatment of DME.</p></div><div class=section><a name=d33664e419 class=n-a></a><h3 class=section-title>Next-generation anti-VEGF-A drugs</h3><p class="" id=d33664e424><b><i>Brolucizumab.</i></b> Brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland) is a humanized single-chain fragment variable binding to VEGF-A and interfering with activation of VEGF receptor 1 and 2 on endothelial cells. A 6-mg dose of brolucizumab delivers a molar dose which is about 11 and 22 times higher than aflibercept 2 mg and ranibizumab 0.5 mg, respectively. In addition, the low molecular weight and high concentration gradient between the vitreous and the retina may increase drug distribution to the target site of action, supporting effective control of anatomical disease activity. The drug has already been shown to be promising for the treatment of neovascularization associated with wet age-related macular degeneration in the HAWK and HARRIER clinical trials<sup><a href="#ref-43">43</a></sup>. Instead, in regard to DME, a phase 3, multi-center, double-masked clinical trial of this agent is ongoing to evaluate the efficacy and safety of brolucizumab in treatment of adult patients with visual disturbance due to DME in comparison with the administration of aflibercept<sup><a href="#ref-44">44</a></sup>. The results will be available in the next few years.</p><p class="" id=d33664e438><b><i>Abicipar pegol.</i></b> Abicipar pegol (Allergan Inc.) belongs to a novel class of small proteins that contain engineered ankyrin repeat domain(s) and bind to target proteins with high specificity and affinity. It is an antagonist of VEGF-A characterized by small size, high potency, and long intravitreal half-life. Results from the phase 2 study showed that abicipar pegol, injected every 8 or 12 weeks in patients affected by DME, offered the functional and anatomical effects with less frequent injections compared with ranibizumab over a 28-week period<sup><a href="#ref-45">45</a></sup>.</p><p class="" id=d33664e448><b><i>Angiopoietin combination drugs.</i></b> Together with VEGF-A, angiopoietin-2 (Ang-2) is considered a key factor in DME pathogenesis. Ang-2 is an antagonist of the Tie2 receptor tyrosine kinase on endothelial cells, counteracting vessel stabilization maintained through Ang-1dependent Tie2 activation. The excess of Ang-2 and VEGF in the retinal tissues promotes vessel destabilization, vascular leakage, and neovascularization. Ang-2 is also involved in inflammatory pathways such as lymphocyte recruitment<sup><a href="#ref-46">46</a><a href="#ref-49">49</a></sup>. Different drugs targeting Ang-2, including RO6867461, a humanized full-length bispecific IgG1 antibody that selectively neutralizes VEGF-A and Ang-2, are in development. A phase III, double-masked, multi-center, randomized study is ongoing to evaluate the efficacy, safety, pharmacokinetics, and optimal treatment frequency of RO6867461 administered by intravitreal injection at 8-week intervals<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d33664e465><b><i>Conbercept (KH902).</i></b> Since its approval in China in 2013, conbercept has been used there for the treatment of neovascular age-related macular degeneration and other retinal vascular diseases, including DME<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. However, it has not yet reached the market in other countries, although, given its excellent safety and efficacy profile, it has gained worldwide attention as a promising option. It is a recombinant fusion protein composed of the second IgG domain of VEGFR1 and the third and fourth domains of VEGFR2 to the constant region (Fc) of human IgG1. The structure is similar to that of aflibercept; however, conbercept has a VEGFR2 kinase insert domain receptor (KDR) Ig-like region 4 (KDRd4) that can improve the three-dimensional structure and increase dimer formation efficiency, thereby increasing the binding capacity of conbercept for VEGF. <i>In vitro</i> experiments have shown that binding of conbercept to VEGF is at least 30 times higher than that of ranibizumab and bevacizumab, achieving the same therapeutic effects but with a lower dose<sup><a href="#ref-53">53</a><a href="#ref-55">55</a></sup>.</p><p class="" id=d33664e489>In patients with DME, the FRONTIER<sup><a href="#ref-56">56</a></sup> and SAILING<sup><a href="#ref-57">57</a></sup> studies showed improvements in visual acuity and corresponding decreases in retinal thickness on optical coherence tomography. More trials on DME are in the planning stages.</p></div><div class=section><a name=d33664e501 class=n-a></a><h3 class=section-title>Combination drugs</h3><p class="" id=d33664e506><b><i>OPT-302.</i></b> OPT-302 (Opthea Limited, South Yarra, Victoria, Australia) binds to VEGF receptor 2 and 3, neutralizing the activity of VEGF-C and -D. A combined use of OPT-302 with the currently available anti-VEGF-A therapy may be responsible for a true total VEGF inhibition. A phase 1b dose escalation study to evaluate OPT-302 in combination with aflibercept showed good results in vision improvement and reductions in retinal swelling<sup><a href="#ref-58">58</a></sup>. A phase 2a randomized controlled clinical study with OPT-302 is ongoing<sup><a href="#ref-58">58</a></sup>.</p><p class="" id=d33664e520><b><i>ALG-1001.</i></b> ALG-1001 (Allegro Ophthalmics, San Juan Capistrano, CA, USA) is a first-in-class integrin peptide therapy. The molecule is able to bind specific integrin receptor sites and works by affecting multiple angiogenic pathways and inflammation. ALG-1001 showed promising results in the phase IIb clinical trial that evaluated it as a sequential therapy or in combination with bevacizumab in patients with DME<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>.</p></div><div class=section><a name=d33664e534 class=n-a></a><h3 class=section-title>Suprachoroidal corticosteroid</h3><p class="" id=d33664e539>Promising technologies for drug delivery currently under investigation include refillable surgical intravitreal implants, encapsulated cell technology, and suprachoroidal drug delivery<sup><a href="#ref-61">61</a></sup>. A phase 1 and 2 exploratory clinical trial examined suprachoroidal triamcinolone acetonide with and without intravitreal aflibercept, demonstrating increased efficacy and durability with the investigational drug<sup><a href="#ref-62">62</a></sup>. Used together with intravitreal aflibercept, suprachoroidal triamcinolone acetonide was generally well tolerated, and no treatment-related serious adverse events were reported in the TYBEE trial through the 24-week evaluation period<sup><a href="#ref-63">63</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33664e558>Management of macular edema: retinal vein occlusion</h2><p class="" id=d33664e561>ME is the main cause of the deterioration of visual acuity in RVO<sup><a href="#ref-64">64</a></sup>. Actually, the first-line therapy in the treatment of ME secondary to RVO is represented by the intravitreal anti-VEGF injections of ranibizumab and aflibercept<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. Moreover, intravitreal corticosteroid agents, such as triamcinolone and dexamethasone implant, have been evaluated<sup><a href="#ref-67">67</a></sup> and are currently considered valid therapeutic options in RVO treatment because of their anti-inflammatory, anti-angiogenic, and anti-edema properties. They are able to improve visual acuity in the short term and have proven especially useful in pseudophakic patients or patients who do not experience significant intraocular pressure elevation with local steroid use. In regard to new therapeutic strategies, Iluvien is not yet approved by the FDA for ME secondary to RVO (see features of Iluvien in the Iluvien section above). Furthermore, two phase 3 studies are planned in order to evaluate the effect of brolucizumab in patients with ME secondary to RVO (see features of brolucizumab in the Brolucizumab section above)<sup><a href="#ref-68">68</a>,<a href="#ref-69">69</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33664e589>Management of macular edema: uveitis</h2><p class="" id=d33664e592>ME is the most common cause of vision impairment in patients with uveitis, affecting 20 to 30% of them<sup><a href="#ref-3">3</a>,<a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>. It is typically associated with intermediate or posterior uveitis or panuveitis and is less frequent in anterior uveitis<sup><a href="#ref-70">70</a>,<a href="#ref-72">72</a></sup>. The treatment of uveitic macular edema (UME) can be challenging because of its relapsing nature and its tendency to persist in many cases despite good control of intraocular inflammation<sup><a href="#ref-72">72</a></sup>. Owing to a lack of prospective randomized controlled clinical trials, an internationally accepted approach to UME has yet to be established.</p><p class="" id=d33664e616>Below, we analyze the main treatments currently in use and the new therapeutic options for non-infectious UME. Infectious UME, conversely, is treated with targeted anti-microbial therapy, and anti-inflammatory treatments should be used after the active infection has been totally controlled<sup><a href="#ref-73">73</a></sup>.</p><div class=section><a name=d33664e623 class=n-a></a><h3 class=section-title>Corticosteroids</h3><p class="" id=d33664e628>Corticosteroids are the mainstay of UME therapy because of their potent and fast-acting anti-inflammatory properties<sup><a href="#ref-74">74</a></sup>. However, short-term use is advised because of the harmful local (that is, cataract and intraocular pressure elevation) and systemic side effects<sup><a href="#ref-75">75</a></sup>.</p><p class="" id=d33664e639><b><i>Topical.</i></b> When inflammation in either subclinical or mild or UME is associated with anterior uveitis, a topical corticosteroid represents the first-line approach. The dose and duration of therapy depend on the underlying cause and the grade of inflammation, beginning with higher doses to be slowly tapered over time<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d33664e649><b><i>Periocular.</i></b> When inflammation is moderate to severe or UME is unresponsive to a topical approach, corticosteroids are administered through periocular depots. Triamcinolone acetonide and methylprednisolone acetate, administered via transeptal or sub-Tenon injections, are the most commonly employed<sup><a href="#ref-77">77</a><a href="#ref-79">79</a></sup>.</p><p class="" id=d33664e662><b><i>Intravitreal.</i></b> Triamcinolone acetonide (Taioftal<sup></sup>, Sooft S.p.a., Montegiorgio, Italy) injection via pars plana has been largely used in UME, and the response has been excellent though brief. It appears to be more effective than periocular triamcinolone but with more side effects<sup><a href="#ref-80">80</a></sup>.</p><p class="" id=d33664e676>The fully biodegradable slow-release implant of dexamethasone (Ozurdex) is delivered for a period of 4 months and its safety and efficacy in non-infectious intermediate and posterior uveitis have been shown by the HURON study group and others<sup><a href="#ref-81">81</a><a href="#ref-83">83</a></sup>. Some studies reported the use of Ozurdex implant in persistent UME secondary to infectious uveitis after total control of active infection<sup><a href="#ref-84">84</a>,<a href="#ref-85">85</a></sup>.</p><p class="" id=d33664e693>Retisert (Bausch + Lomb, Rochester, NY, USA) is a non-biodegradable FAc 0.59-mg implant surgically implanted through the pars plana and sutured to the sclera. The MUST trial showed the overall superiority of FAc implant in controlling non-infectious uveitis compared with systemic therapy<sup><a href="#ref-86">86</a></sup>.</p><p class="" id=d33664e700>Iluvien is a non-biodegradable depot of 0.19-mg FAc approved for the treatment of DME. Iluvien is currently in randomized controlled clinical trials for the treatment of non-infectious uveitis<sup><a href="#ref-87">87</a></sup>.</p><p class="" id=d33664e707><b><i>Systemic.</i></b> Systemic corticosteroids are effective in treating UME, especially when bilateral, but systemic adverse effects prevent their long-term use. Prednisone is the most commonly used, and dosing and tapering should be individualized to the patient<sup><a href="#ref-88">88</a></sup>.</p></div><div class=section><a name=d33664e718 class=n-a></a><h3 class=section-title>Non-biologic immunomodulatory agents</h3><p class="" id=d33664e723>Non-biologic immunomodulatory drugs are used as a second-line treatment for UME as corticosteroid-sparing agents. There are no randomized controlled trials toward the efficacy of these medications specifically on UME<sup><a href="#ref-89">89</a></sup>. Non-biologic immunomodulatory drugs include anti-metabolites (azathioprine, methotrexate, and mycophenolate mofetil), inhibitors of T-cell signaling (cyclosporine A, tacrolimus, and sirolimus), and alkylating agents (cyclophosphamide).</p><p class="" id=d33664e730>Azathioprine, methotrexate, and mycophenolate mofetil showed some efficacy in the treatment of UME secondary to different non-infectious uveitis<sup><a href="#ref-90">90</a><a href="#ref-94">94</a></sup>.</p><p class="" id=d33664e740>Cyclosporine A and tacrolimus are both effective in patients with uveitis, but few data exist when referring specifically to UME<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>. Intravitreal sirolimus presents a better safety profile than subcutaneous route with good control of inflammation and improvement of UME, but the results of SAVE studies demonstrated that frequent reinjections are needed<sup><a href="#ref-97">97</a><a href="#ref-99">99</a></sup>.</p><p class="" id=d33664e757>Cyclophosphamide inhibits both RNA transcription and DNA duplication. The SITE cohort study showed good control of inflammation with cyclophosphamide with a non-statistically significant increase in cancer-related mortality rates<sup><a href="#ref-100">100</a></sup>.</p></div><div class=section><a name=d33664e766 class=n-a></a><h3 class=section-title>Biologic immunomodulatory agents</h3><p class="" id=d33664e771>Biologic immunomodulatory agents are humanized antibodies used for recalcitrant UME despite steroidal or traditional immunosuppressive treatments or both. Their main adverse effects include exacerbation of infectious and autoimmune diseases.</p><p class="" id=d33664e774>Tumor necrosis factor alpha blockers (anti-TNF-) inhibit TNF-, a pro-inflammatory cytokine considered crucial in the pathogenesis of different uveitis<sup><a href="#ref-101">101</a></sup>. Adalimumab (Humira; AbbVie Inc., North Chicago, IL, USA) is currently the only systemic non-corticosteroid agent which has been approved by the FDA for the treatment of non-infectious intermediate uveitis, posterior uveitis, or panuveitis in adults and children more than 2 years old. Many studies have shown improvement in macular thickness after systemic adalimumab but not after intravitreal administration<sup><a href="#ref-101">101</a><a href="#ref-104">104</a></sup>.</p><p class="" id=d33664e788>Infliximab (Remicade<sup></sup>, Janssen Biotech, Inc., Horsham, PA, USA) is an anti-TNF- administered intravenously. Like adalimumab, infliximab has shown positive results with systemic delivery and but not with an intravitreal route of administration<sup><a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>.</p><p class="" id=d33664e801>Golimumab (Simponi<sup></sup>, Janssen Biotech Inc.) is another anti-TNF- whose efficacy in UME has been demonstrated in case reports and small case series. Large control studies are required<sup><a href="#ref-107">107</a>,<a href="#ref-108">108</a></sup>.</p><p class="" id=d33664e815>Etanercept (Enbrel<sup></sup>, Immunex Corporation, Seattle, WA, USA) is a fusion protein that blocks TNF- and TNF- and has been found to be ineffective for uveitis treatment. Its use has been discouraged in many case series<sup><a href="#ref-93">93</a>,<a href="#ref-109">109</a></sup>.</p><p class="" id=d33664e828>Tocilizumab (Actemra<sup></sup>, Genentech Inc., San Francisco, CA, USA) blocks interleukin-6 (IL-6), a strong pro-inflammatory cytokine. Several studies have demonstrated efficacy in UME refractory to previous treatments in different types of uveitis<sup><a href="#ref-110">110</a>,<a href="#ref-111">111</a></sup>.</p><p class="" id=d33664e841>Rituximab (Rituxan<sup></sup>, Genentech Inc.) targets CD20, which is the differentiation cluster of mature B cells. Multi-centered randomized controlled trials are lacking, but small case series have demonstrated beneficial effects in the treatment of non-infectious uveitis and UME<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>.</p><p class="" id=d33664e854>Many other moleculessuch as abatacept (Orencia<sup></sup>, Bristol-Myers Squibb Company, New York, NY, USA), a T-lymphocyte inhibitor; gevokizumab (XOMA 052, XOMA Corporation, Berkeley, CA, USA), an anti-IL-1; ustekinumab (Stelara, Janssen-Cilag International NV, Beerse, Belgium), an anti-IL-12 and anti-IL-23; and filgotinib (GLPG0634), a janus kinase 1are under investigation in different phase 2 clinical trials with promising results<sup><a href="#ref-114">114</a><a href="#ref-120">120</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33664e871>Conclusions</h2><p class="" id=d33664e874>ME is a major complication of several vascular and inflammatory retinal diseases and multiple mechanisms are implicated in its development. During the acute phase of ME development, there is a visual function decline that often is reversible after the resolution of the edema (spontaneous resolution or after treatment). On the other hand, long-standing ME causes irreversible anatomical changes of the retina, leading to a permanent impairment of visual function. For these reasons, ophthalmologists should treat ME in the early phases of development in order to avoid irreversible damage of visual function.</p><p class="" id=d33664e877>The treatment of ME changes depending on the causative disease. In the DR, different intravitreal drugs for the treatment of DME, such as anti-VEGF injections (ranibizumab and aflibercept) and intravitreal corticosteroids (Ozurdex and Iluvien), are available. However, despite the strong efficacy achieved with these drugs, a significant proportion of patients with DME do not achieve anatomical or functional improvements. For this reason, new drugs are needed in the treatment of persistent or resistant forms of DME. Some of the drugs described here, especially brolucizumab and abicipar pegol, have been shown to be effective in preliminary studies, and these are probably the ones that have a better chance of soon being approved for the treatment of DME.</p><p class="" id=d33664e880>Also, for ME secondary to RVO, the therapeutic options are very similar to those for DME. However, Iluvien is not yet FDA-approved for the treatment of ME secondary to RVO.</p><p class="" id=d33664e883>ME secondary to uveitis is another important complication. In this case, a crucial role is played by corticosteroids (topical, periocular, intravitreal, and systemic) and non-biologic immunomodulatory drugs. However, in several cases, there is no resolution of UME, and the introduction into clinical practice of new biologic agents is an important new therapeutic option. Some of these new drugs (that is, adalimumab) have been approved by the FDA whereas several others are under investigation. Nonetheless, first it will be important to prove the safety and efficacy of these new drugs. Only after that will we have new therapeutic options in the treatment of UME.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d33664e890>Abbreviations</h2><p class="" id=d33664e893>Ang, angiopoietin; DME, diabetic macular edema; DR, diabetic retinopathy; FAc, fluocinolone acetonide; FDA, US Food and Drug Administration; IL, interleukin; ME, macular edema; RVO, retinal vein occlusion; TNF, tumor necrosis factor; UME, uveitic macular edema; VEGF, vascular endothelial growth factor</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d33664e1 class=n-a></a><h2 class=main-title id=d34004>Author contributions</h2><p class=metadata-entry><a name=d33664e151 class=n-a></a><p id=d33664e153> All of the authors made substantial contributions to the conception, acquisition, and interpretation of data; drafted the work or revised it critically for important intellectual content; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></p></div><div class=back-section><a name=d33664e1 class=n-a></a><h2 class=main-title id=d34006>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d33664e900 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d34366>References</h2><div class="section ref-list"><a name=d33664e900 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d33664e907 class=n-a></a>Yau JW, Rogers SL, Kawasaki R, <i> et al.</i>: Global prevalence and major risk factors of diabetic retinopathy. <i>Diabetes Care.</i> 2012; <b>35</b>(3): 55664. <a target=xrefwindow id=d33664e918 href="http://www.ncbi.nlm.nih.gov/pubmed/22301125">PubMed Abstract </a> | <a target=xrefwindow id=d33664e921 href="https://doi.org/10.2337/dc11-1909">Publisher Full Text </a> | <a target=xrefwindow id=d33664e925 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3322721">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d33664e934 class=n-a></a>Rogers S, McIntosh RL, Cheung N, <i> et al.</i>: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. <i>Ophthalmology.</i> 2010; <b>117</b>(2): 3139.e1. <a target=xrefwindow id=d33664e945 href="http://www.ncbi.nlm.nih.gov/pubmed/20022117">PubMed Abstract </a> | <a target=xrefwindow id=d33664e948 href="https://doi.org/10.1016/j.ophtha.2009.07.017">Publisher Full Text </a> | <a target=xrefwindow id=d33664e952 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2945292">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d33664e961 class=n-a></a>Rothova A, Suttorp-van Schulten MS, Frits Treffers W, <i> et al.</i>: Causes and frequency of blindness in patients with intraocular inflammatory disease. <i>Br J Ophthalmol.</i> 1996; <b>80</b>(4): 3326. <a target=xrefwindow id=d33664e972 href="http://www.ncbi.nlm.nih.gov/pubmed/8703885">PubMed Abstract </a> | <a target=xrefwindow id=d33664e975 href="https://doi.org/10.1136/bjo.80.4.332">Publisher Full Text </a> | <a target=xrefwindow id=d33664e979 href="http://www.ncbi.nlm.nih.gov/pmc/articles/505460">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d33664e988 class=n-a></a>Daruich A, Matet A, Moulin A, <i> et al.</i>: Mechanisms of macular edema: Beyond the surface. <i>Prog Retin Eye Res.</i> 2018; <b>63</b>: 2068. <a target=xrefwindow id=d33664e999 href="http://www.ncbi.nlm.nih.gov/pubmed/29126927">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1002 href="https://doi.org/10.1016/j.preteyeres.2017.10.006">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d33664e1011 class=n-a></a>Kohno T, Ishibashi T, Inomata H, <i> et al.</i>: Experimental macular edema of commotio retinae: preliminary report. <i>Jpn J Ophthalmol.</i> 1983; <b>27</b>(1): 14956. <a target=xrefwindow id=d33664e1022 href="http://www.ncbi.nlm.nih.gov/pubmed/6855008">PubMed Abstract </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d33664e1032 class=n-a></a>Yanoff M, Fine BS, Brucker AJ, <i> et al.</i>: Pathology of human cystoid macular edema. <i>Surv Ophthalmol.</i> 1984; <b>28 Suppl</b>: 50511. <a target=xrefwindow id=d33664e1043 href="http://www.ncbi.nlm.nih.gov/pubmed/6463850">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1046 href="https://doi.org/10.1016/0039-6257(84)90233-9">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d33664e1055 class=n-a></a>Bradbury MW, Lightman SL: The blood-brain interface. <i>Eye (Lond).</i> 1990; <b>4</b>(Pt 2): 24954. <a target=xrefwindow id=d33664e1063 href="http://www.ncbi.nlm.nih.gov/pubmed/2199234">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1066 href="https://doi.org/10.1038/eye.1990.36">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d33664e1075 class=n-a></a>Trnquist P, Alm A, Bill A: Permeability of ocular vessels and transport across the blood-retinal-barrier. <i>Eye (Lond).</i> 1990; <b>4</b>(Pt 2): 3039. <a target=xrefwindow id=d33664e1083 href="http://www.ncbi.nlm.nih.gov/pubmed/2199237">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1086 href="https://doi.org/10.1038/eye.1990.41">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d33664e1095 class=n-a></a>Fruttiger M: Development of the retinal vasculature. <i>Angiogenesis.</i> 2007; <b>10</b>(2): 7788. <a target=xrefwindow id=d33664e1103 href="http://www.ncbi.nlm.nih.gov/pubmed/17322966">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1106 href="https://doi.org/10.1007/s10456-007-9065-1">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d33664e1115 class=n-a></a>Klaassen I, van Noorden CJ, Schlingemann RO: Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. <i>Prog Retin Eye Res.</i> 2013; <b>34</b>: 1948. <a target=xrefwindow id=d33664e1123 href="http://www.ncbi.nlm.nih.gov/pubmed/23416119">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1126 href="https://doi.org/10.1016/j.preteyeres.2013.02.001">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d33664e1135 class=n-a></a>Sorrentino FS, Allkabes M, Salsini G, <i> et al.</i>: The importance of glial cells in the homeostasis of the retinal microenvironment and their pivotal role in the course of diabetic retinopathy. <i>Life Sci.</i> 2016; <b>162</b>: 549. <a target=xrefwindow id=d33664e1146 href="http://www.ncbi.nlm.nih.gov/pubmed/27497914">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1149 href="https://doi.org/10.1016/j.lfs.2016.08.001">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d33664e1159 class=n-a></a>Omri S, Omri B, Savoldelli M, <i> et al.</i>: The outer limiting membrane (OLM) revisited: clinical implications. <i>Clin Ophthalmol.</i> 2010; <b>4</b>: 18395. <a target=xrefwindow id=d33664e1170 href="http://www.ncbi.nlm.nih.gov/pubmed/20463783">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1173 href="https://doi.org/10.2147/opth.s5901">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1177 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2861922">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d33664e1186 class=n-a></a>Achiron A, Lagstein O, Glick M, <i> et al.</i>: Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities. <i>Acta Ophthalmol.</i> 2015; <b>93</b>(8): e649e653. <a target=xrefwindow id=d33664e1197 href="http://www.ncbi.nlm.nih.gov/pubmed/25899144">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1200 href="https://doi.org/10.1111/aos.12735">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d33664e1209 class=n-a></a>Munk M, Kiss C, Huf W, <i> et al.</i>: Therapeutic interventions for macular diseases show characteristic effects on near and distance visual function. <i>Retina.</i> 2013; <b>33</b>(9): 191522. <a target=xrefwindow id=d33664e1220 href="http://www.ncbi.nlm.nih.gov/pubmed/23584693">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1223 href="https://doi.org/10.1097/IAE.0b013e318285cc0c">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d33664e1232 class=n-a></a>Otani T, Yamaguchi Y, Kishi S: Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. <i>Retina.</i> 2010; <b>30</b>(5): 77480. <a target=xrefwindow id=d33664e1240 href="http://www.ncbi.nlm.nih.gov/pubmed/19996821">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1243 href="https://doi.org/10.1097/IAE.0b013e3181c2e0d6">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d33664e1252 class=n-a></a>Wakabayashi T, Oshima Y, Fujimoto H, <i> et al.</i>: Foveal microstructure and visual acuity after retinal detachment repair: imaging analysis by Fourier-domain optical coherence tomography. <i>Ophthalmology.</i> 2009; <b>116</b>(3): 51928. <a target=xrefwindow id=d33664e1263 href="http://www.ncbi.nlm.nih.gov/pubmed/19147231">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1266 href="https://doi.org/10.1016/j.ophtha.2008.10.001">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d33664e1275 class=n-a></a>Sun JK, Radwan SH, Soliman AZ, <i> et al.</i>: Neural Retinal Disorganization as a Robust Marker of Visual Acuity in Current and Resolved Diabetic Macular Edema. <i>Diabetes.</i> 2015; <b>64</b>(7): 256070. <a target=xrefwindow id=d33664e1286 href="http://www.ncbi.nlm.nih.gov/pubmed/25633419">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1289 href="https://doi.org/10.2337/db14-0782">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1293 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4477364">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d33664e1303 class=n-a></a>Sacconi R, Corbelli E, Carnevali A, <i> et al.</i>: Optical coherence tomography angiography in pseudophakic cystoid macular oedema compared to diabetic macular oedema: qualitative and quantitative evaluation of retinal vasculature. <i>Br J Ophthalmol.</i> 2018; <b>102</b>(12): 168490. <a target=xrefwindow id=d33664e1314 href="http://www.ncbi.nlm.nih.gov/pubmed/29463502">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1317 href="https://doi.org/10.1136/bjophthalmol-2017-311240">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d33664e1326 class=n-a></a>Gass JD, Blodi BA: Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. <i>Ophthalmology.</i> 1993; <b>100</b>(10): 153646. <a target=xrefwindow id=d33664e1334 href="http://www.ncbi.nlm.nih.gov/pubmed/8414413">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1337 href="https://doi.org/10.1016/S0161-6420(93)31447-8">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d33664e1346 class=n-a></a>Charbel Issa P, Gillies MC, Chew EY, <i> et al.</i>: Macular telangiectasia type 2. <i>Prog Retin Eye Res.</i> 2013; <b>34</b>: 4977. <a target=xrefwindow id=d33664e1357 href="http://www.ncbi.nlm.nih.gov/pubmed/23219692">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1360 href="https://doi.org/10.1016/j.preteyeres.2012.11.002">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3638089">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d33664e1373 class=n-a></a>Sacconi R, Freund KB, Yannuzzi LA, <i> et al.</i>: The Expanded Spectrum of Perifoveal Exudative Vascular Anomalous Complex. <i>Am J Ophthalmol.</i> 2017; <b>184</b>: 13746. <a target=xrefwindow id=d33664e1384 href="http://www.ncbi.nlm.nih.gov/pubmed/29079450">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1387 href="https://doi.org/10.1016/j.ajo.2017.10.009">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d33664e1396 class=n-a></a>Ehlers JP, Rayess H, Steinle N: Topical dorzolamide therapy for taxane-related macular oedema. <i>Eye (Lond).</i> 2013; <b>27</b>(1): 1024. <a target=xrefwindow id=d33664e1404 href="http://www.ncbi.nlm.nih.gov/pubmed/23154489">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1407 href="https://doi.org/10.1038/eye.2012.228">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1410 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3545372">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d33664e1419 class=n-a></a>Duncan KE, Chang LY, Patronas M: MEK inhibitors: A new class of chemotherapeutic agents with ocular toxicity. <i>Eye (Lond).</i> 2015; <b>29</b>(8): 100312. <a target=xrefwindow id=d33664e1427 href="http://www.ncbi.nlm.nih.gov/pubmed/26043707">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1430 href="https://doi.org/10.1038/eye.2015.82">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4541356">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729659763"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1443 class=n-a></a>Bilge AD, Yaylali SA, Yavuz S, <i> et al.</i>: Bilateral serous macular detachment in a patient with nephrotic syndrome. <i>Retin Cases Brief Rep.</i> 2018; <b>12</b>(3): 2602. <a target=xrefwindow id=d33664e1454 href="http://www.ncbi.nlm.nih.gov/pubmed/27984544">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1457 href="https://doi.org/10.1097/ICB.0000000000000487">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729659763">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d33664e1470 class=n-a></a>Sarraf D, Rahimy E, Fawzi AA, <i> et al.</i>: Paracentral acute middle maculopathy: a new variant of acute macular neuroretinopathy associated with retinal capillary ischemia. <i>JAMA Ophthalmol.</i> 2013; <b>131</b>(10): 127587. <a target=xrefwindow id=d33664e1481 href="http://www.ncbi.nlm.nih.gov/pubmed/23929382">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1484 href="https://doi.org/10.1001/jamaophthalmol.2013.4056">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d33664e1493 class=n-a></a>Sacconi R, Baldin G, Carnevali A, <i> et al.</i>: Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. <i>Eye (Lond).</i> 2018; <b>32</b>(4): 73442. <a target=xrefwindow id=d33664e1504 href="http://www.ncbi.nlm.nih.gov/pubmed/29303152">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1507 href="https://doi.org/10.1038/eye.2017.295">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1511 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5898870">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d33664e1520 class=n-a></a>Das A, McGuire PG, Rangasamy S: Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. <i>Ophthalmology.</i> 2015; <b>122</b>(7): 137594. <a target=xrefwindow id=d33664e1528 href="http://www.ncbi.nlm.nih.gov/pubmed/25935789">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1531 href="https://doi.org/10.1016/j.ophtha.2015.03.024">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11592959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1540 class=n-a></a>Mitchell P, Bandello F, Schmidt-Erfurth U, <i> et al.</i>: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. <i>Ophthalmology.</i> 2011; <b>118</b>(4): 61525. <a target=xrefwindow id=d33664e1551 href="http://www.ncbi.nlm.nih.gov/pubmed/21459215">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1554 href="https://doi.org/10.1016/j.ophtha.2011.01.031">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11592959">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14267151"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1567 class=n-a></a>Nguyen QD, Brown DM, Marcus DM, <i> et al.</i>: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. <i>Ophthalmology.</i> 2012; <b>119</b>(4): 789801. <a target=xrefwindow id=d33664e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/22330964">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1581 href="https://doi.org/10.1016/j.ophtha.2011.12.039">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14267151">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d33664e1595 class=n-a></a>Brown DM, Nguyen QD, Marcus DM, <i> et al.</i>: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. <i>Ophthalmology.</i> 2013; <b>120</b>(10): 201322. <a target=xrefwindow id=d33664e1606 href="http://www.ncbi.nlm.nih.gov/pubmed/23706949">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1609 href="https://doi.org/10.1016/j.ophtha.2013.02.034">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d33664e1618 class=n-a></a>Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, <i> et al.</i>: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. <i>N Engl J Med.</i> 2015; <b>372</b>(13): 1193203. <a target=xrefwindow id=d33664e1629 href="http://www.ncbi.nlm.nih.gov/pubmed/25692915">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1632 href="https://doi.org/10.1056/NEJMoa1414264">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4422053">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726762577"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1645 class=n-a></a>Heier JS, Korobelnik JF, Brown DM, <i> et al.</i>: Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. <i>Ophthalmology.</i> 2016; <b>123</b>(11): 237685. <a target=xrefwindow id=d33664e1656 href="http://www.ncbi.nlm.nih.gov/pubmed/27651226">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1659 href="https://doi.org/10.1016/j.ophtha.2016.07.032">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726762577">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730127602"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1672 class=n-a></a>Cai S, Bressler NM: Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. <i>Curr Opin Ophthalmol.</i> 2017; <b>28</b>(6): 63643. <a target=xrefwindow id=d33664e1680 href="http://www.ncbi.nlm.nih.gov/pubmed/28837425">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1683 href="https://doi.org/10.1097/ICU.0000000000000424">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730127602">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736297811"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1696 class=n-a></a>de Andrade GC, de Oliveira Dias JR, Maia A, <i> et al.</i>: Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes. <i>Ophthalmic Surg Lasers Imaging Retina.</i> 2018; <b>49</b>(4): 24550. <a target=xrefwindow id=d33664e1707 href="http://www.ncbi.nlm.nih.gov/pubmed/29664981">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1710 href="https://doi.org/10.3928/23258160-20180329-06">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736297811">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732442750"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1723 class=n-a></a>Mansour AM, Ashraf M, Charbaji A, <i> et al.</i>: Two-year outcomes of intravitreal ziv-aflibercept. <i>Br J Ophthalmol.</i> 2018; <b>102</b>(10): 138790. <a target=xrefwindow id=d33664e1734 href="http://www.ncbi.nlm.nih.gov/pubmed/29317400">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1737 href="https://doi.org/10.1136/bjophthalmol-2017-311591">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732442750">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718438658"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1751 class=n-a></a>Boyer DS, Yoon YH, Belfort R Jr, <i> et al.</i>: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. <i>Ophthalmology.</i> 2014; <b>121</b>(10): 190414. <a target=xrefwindow id=d33664e1762 href="http://www.ncbi.nlm.nih.gov/pubmed/24907062">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1765 href="https://doi.org/10.1016/j.ophtha.2014.04.024">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718438658">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d33664e1778 class=n-a></a>Smiddy WE: Economic considerations of macular edema therapies. <i>Ophthalmology.</i> 2011; <b>118</b>(9): 182733. <a target=xrefwindow id=d33664e1786 href="http://www.ncbi.nlm.nih.gov/pubmed/21507488">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1789 href="https://doi.org/10.1016/j.ophtha.2010.12.034">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3483086">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d33664e1801 class=n-a></a>Lang GE, Berta A, Eldem BM, <i> et al.</i>: Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. <i>Ophthalmology.</i> 2013; <b>120</b>(10): 200412. <a target=xrefwindow id=d33664e1812 href="http://www.ncbi.nlm.nih.gov/pubmed/23725735">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1815 href="https://doi.org/10.1016/j.ophtha.2013.02.019">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d33664e1824 class=n-a></a>Virgili G, Parravano M, Menchini F, <i> et al.</i>: Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations? <i>Br J Ophthalmol.</i> 2014; <b>98</b>(4): 4212. <a target=xrefwindow id=d33664e1835 href="http://www.ncbi.nlm.nih.gov/pubmed/23786886">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1838 href="https://doi.org/10.1136/bjophthalmol-2013-303352">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717950703"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1847 class=n-a></a>Campochiaro PA, Brown DM, Pearson A, <i> et al.</i>: Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. <i>Ophthalmology.</i> 2012; <b>119</b>(10): 212532. <a target=xrefwindow id=d33664e1858 href="http://www.ncbi.nlm.nih.gov/pubmed/22727177">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1861 href="https://doi.org/10.1016/j.ophtha.2012.04.030">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717950703">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736297813"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1874 class=n-a></a>Bailey C, Chakravarthy U, Lotery A, <i> et al.</i>: Real-world experience with 0.2g/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. <i>Eye (Lond).</i> 2017; <b>31</b>(12): 170715. <a target=xrefwindow id=d33664e1885 href="http://www.ncbi.nlm.nih.gov/pubmed/28737758">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1888 href="https://doi.org/10.1038/eye.2017.125">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1892 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5733285">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736297813">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733207164"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1906 class=n-a></a>Fusi-Rubiano W, Mukherjee C, Lane M, <i> et al.</i>: Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien) at 2 years. <i>BMC Ophthalmol.</i> 2018; <b>18</b>(1): 62. <a target=xrefwindow id=d33664e1917 href="http://www.ncbi.nlm.nih.gov/pubmed/29486754">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1920 href="https://doi.org/10.1186/s12886-018-0726-1">Publisher Full Text </a> | <a target=xrefwindow id=d33664e1924 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6389097">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733207164">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735560218"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e1937 class=n-a></a>Dugel PU, Koh A, Ogura Y, <i> et al.</i>: HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology.</i> 2019; pii: S0161-6420(18)33018-5. <a target=xrefwindow id=d33664e1945 href="http://www.ncbi.nlm.nih.gov/pubmed/30986442">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1948 href="https://doi.org/10.1016/j.ophtha.2019.04.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735560218">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d33664e1961 class=n-a></a>Novartis Pharmaceuticals: Study of efficacy and safety of Brolucizumab vs. Aflibercept in Patients with visual impairment due to diabetic macular edema (KESTREL). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e1963 href="https://clinicaltrials.gov/ct2/show/NCT03481634">Reference Source</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d33664e1972 class=n-a></a>Hassan TS: A multicenter, double masked phase 2 clinical trial evaluating abicipar pegol for diabetic macular edema. Paper presented at: American Academy of Ophthalmology Annual Meeting; October 14-18; Chicago, IL, 2016.</span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d33664e1981 class=n-a></a>Aiello LP, Avery RL, Arrigg PG, <i> et al.</i>: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. <i>N Engl J Med.</i> 1994; <b>331</b>(22): 14807. <a target=xrefwindow id=d33664e1992 href="http://www.ncbi.nlm.nih.gov/pubmed/7526212">PubMed Abstract </a> | <a target=xrefwindow id=d33664e1995 href="https://doi.org/10.1056/NEJM199412013312203">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d33664e2004 class=n-a></a>Davis S, Aldrich TH, Jones PF, <i> et al.</i>: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. <i>Cell.</i> 1996; <b>87</b>(7): 11619. <a target=xrefwindow id=d33664e2015 href="http://www.ncbi.nlm.nih.gov/pubmed/8980223">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2018 href="https://doi.org/10.1016/s0092-8674(00)81812-7">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d33664e2028 class=n-a></a>Maisonpierre PC, Suri C, Jones PF, <i> et al.</i>: Angiopoietin-2, a natural antagonist for Tie2 that disrupts <i>in vivo</i> angiogenesis. <i>Science.</i> 1997; <b>277</b>(5322): 5560. <a target=xrefwindow id=d33664e2042 href="http://www.ncbi.nlm.nih.gov/pubmed/9204896">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2046 href="https://doi.org/10.1126/science.277.5322.55">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d33664e2055 class=n-a></a>Fiedler U, Krissl T, Koidl S, <i> et al.</i>: Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. <i>J Biol Chem.</i> 2003; <b>278</b>(3): 17217. <a target=xrefwindow id=d33664e2066 href="http://www.ncbi.nlm.nih.gov/pubmed/12427764">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2069 href="https://doi.org/10.1074/jbc.M208550200">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d33664e2078 class=n-a></a>Hoffmann-La Roche: A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e2080 href="https://clinicaltrials.gov/ct2/show/NCT03622580">Reference Source</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729158209"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2089 class=n-a></a>Xu Y, Rong A, Bi Y, <i> et al.</i>: Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. <i>J Ophthalmol.</i> 2016; <b>2016</b>: 2143082. <a target=xrefwindow id=d33664e2100 href="http://www.ncbi.nlm.nih.gov/pubmed/27777791">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2103 href="https://doi.org/10.1155/2016/2143082">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5061960">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729158209">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736297817"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2120 class=n-a></a>Xu Y, Rong A, Xu W, <i> et al.</i>: Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. <i>BMC Ophthalmol.</i> 2017; <b>17</b>(1): 158. <a target=xrefwindow id=d33664e2131 href="http://www.ncbi.nlm.nih.gov/pubmed/28841827">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2134 href="https://doi.org/10.1186/s12886-017-0554-8">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2138 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6389086">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736297817">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d33664e2151 class=n-a></a>Zhang M, Yu D, Yang C, <i> et al.</i>: The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. <i>Pharm Res.</i> 2009; <b>26</b>(1): 20410. <a target=xrefwindow id=d33664e2162 href="http://www.ncbi.nlm.nih.gov/pubmed/18854954">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2165 href="https://doi.org/10.1007/s11095-008-9718-9">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d33664e2175 class=n-a></a>Zhang M, Zhang J, Yan M, <i> et al.</i>: Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. <i>Mol Vis.</i> 2008; <b>14</b>: 3749. <a target=xrefwindow id=d33664e2186 href="http://www.ncbi.nlm.nih.gov/pubmed/18246030">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2189 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2267739">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d33664e2198 class=n-a></a>Wang F, Bai Y, Yu W, <i> et al.</i>: Anti-angiogenic effect of KH902 on retinal neovascularization. <i>Graefes Arch Clin Exp Ophthalmol.</i> 2013; <b>251</b>(19): 21319. <a target=xrefwindow id=d33664e2209 href="http://www.ncbi.nlm.nih.gov/pubmed/23740520">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2212 href="https://doi.org/10.1007/s00417-013-2392-6">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d33664e2221 class=n-a></a>Chengdu Kanghong Biotech Co: Safety and efficacy by multiple injection of KH902 in patients with diabetic macular edema (DME) (Frontier-1). In: ClinicalTrials.gov [cited 2019 Jul 15]. <a target=xrefwindow id=d33664e2223 href="https://clinicaltrials.gov/ct2/show/NCT01324869">Reference Source</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d33664e2232 class=n-a></a>Chengdu Kanghong Biotech Co: Safety and efficacy study of conbercept in diabetic macular edema (DME) (Sailing). In: ClinicalTrials.gov [cited 2019 Jul 15]. <a target=xrefwindow id=d33664e2234 href="https://clinicaltrials.gov/ct2/show/NCT02194634">Reference Source</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d33664e2243 class=n-a></a>Opthea Limited: A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema. In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e2245 href="https://clinicaltrials.gov/ct2/show/NCT03397264">Reference Source</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d33664e2254 class=n-a></a>Kaiser PK: Topline results from prospective, double-masked, placebo controlled phase 2b clinical study evaluating Luminate in patients with diabetic macular edema. Paper presented at: Association for Research in Vision and Ophthalmology Annual Meeting; Washington, DC. 2017.</span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d33664e2264 class=n-a></a>Boyer DS: Human phase 2 clinical studies update. DEL MAR Phase 2B. Paper presented at: Angiogenesis 2017; Miami, FL, 2017.</span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d33664e2273 class=n-a></a>Pearce W, Hsu J, Yeh S: Advances in drug delivery to the posterior segment. <i>Curr Opin Ophthalmol.</i> 2015; <b>26</b>(3): 2339. <a target=xrefwindow id=d33664e2281 href="http://www.ncbi.nlm.nih.gov/pubmed/25759965">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2284 href="https://doi.org/10.1097/ICU.0000000000000143">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4575283">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d33664e2296 class=n-a></a>Wykoff CC: Suprachoroidal triamcinolone acetonide with and without intravitreal aflibercept for diabetic macular edema: Phase 1/2 HULK study. Paper presented at American Academy of Ophthalmology Retina Subspecialty Day; November 10-11, New Orleans, LA. 2017. </span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d33664e2305 class=n-a></a>Clearside Biomedical, Inc: Suprachoroidal CLS-TA with intravitreal aflibercept versus aflibercept alone in subject with diabetic macular edema (TYBEE). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e2307 href="https://clinicaltrials.gov/ct2/show/NCT03126786">Reference Source</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d33664e2316 class=n-a></a>Hayreh SS: Ocular vascular occlusive disorders: natural history of visual outcome. <i>Prog Retin Eye Res.</i> 2014; <b>41</b>: 125. <a target=xrefwindow id=d33664e2324 href="http://www.ncbi.nlm.nih.gov/pubmed/24769221">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2327 href="https://doi.org/10.1016/j.preteyeres.2014.04.001">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2330 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4073304">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976315"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2339 class=n-a></a>Holz FG, Roider J, Ogura Y, <i> et al.</i>: VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. <i>Br J Ophthalmol.</i> 2013; <b>97</b>(3): 27884. <a target=xrefwindow id=d33664e2350 href="http://www.ncbi.nlm.nih.gov/pubmed/23298885">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2353 href="https://doi.org/10.1136/bjophthalmol-2012-301504">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976315">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d33664e2367 class=n-a></a>Boyer D, Heier J, Brown DM, <i> et al.</i>: Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. <i>Ophthalmology.</i> 2012; <b>119</b>(5): 102432. <a target=xrefwindow id=d33664e2378 href="http://www.ncbi.nlm.nih.gov/pubmed/22440275">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2381 href="https://doi.org/10.1016/j.ophtha.2012.01.042">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d33664e2390 class=n-a></a>Haller JA, Bandello F, Belfort R Jr, <i> et al.</i>: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. <i>Ophthalmology.</i> 2010; <b>117</b>(6): 11341146.e3. <a target=xrefwindow id=d33664e2401 href="http://www.ncbi.nlm.nih.gov/pubmed/20417567">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2404 href="https://doi.org/10.1016/j.ophtha.2010.03.032">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d33664e2413 class=n-a></a>Novartis Pharmaceuticals: Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e2415 href="https://clinicaltrials.gov/ct2/show/NCT03810313">Reference Source</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d33664e2424 class=n-a></a>Novartis Pharmaceuticals: Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e2426 href="https://clinicaltrials.gov/ct2/show/NCT03802630">Reference Source</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736297818"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2435 class=n-a></a>Cunningham ET, Zierhut M: Uveitic Macular Edema. <i>Ocul Immunol Inflamm.</i> 2018; <b>26</b>(7): 98790. <a target=xrefwindow id=d33664e2443 href="https://doi.org/10.1080/09273948.2018.1529466">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736297818">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d33664e2456 class=n-a></a>Bodaghi B, Cassoux N, Wechsler B, <i> et al.</i>: Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. <i>Medicine (Baltimore).</i> 2001; <b>80</b>(4): 26370. <a target=xrefwindow id=d33664e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/11470987">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2470 href="https://doi.org/10.1097/00005792-200107000-00005">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d33664e2480 class=n-a></a>Preble JM, Foster CS: Uveitic macular edema: A stepladder treatment paradigm. <i>Clinical Investigation.</i> 2015; <b>5</b>(5): 50917. <a target=xrefwindow id=d33664e2488 href="https://www.researchgate.net/profile/C_Foster3/publication/277900716_Uveitic_macular_edema_a_stepladder_treatment_paradigm/links/5615154008ae4ce3cc651004.pdf">Reference Source</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735793252"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2497 class=n-a></a>Koronis S, Stavrakas P, Balidis M, <i> et al.</i>: Update in treatment of uveitic macular edema. <i>Drug Des Devel Ther.</i> 2019; <b>13</b>: 66780. <a target=xrefwindow id=d33664e2508 href="http://www.ncbi.nlm.nih.gov/pubmed/30858697">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2511 href="https://doi.org/10.2147/DDDT.S166092">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2515 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6387597">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735793252">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d33664e2528 class=n-a></a>Babu K, Mahendradas P: Medical management of uveitis - current trends. <i>Indian J Ophthalmol.</i> 2013; <b>61</b>(6): 27783. <a target=xrefwindow id=d33664e2536 href="http://www.ncbi.nlm.nih.gov/pubmed/23803479">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2539 href="https://doi.org/10.4103/0301-4738.114099">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2542 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3744780">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732438322"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2551 class=n-a></a>Dick AD, Rosenbaum JT, Al-Dhibi HA, <i> et al.</i>: Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. <i>Ophthalmology.</i> 2018; <b>125</b>(5): 75773. <a target=xrefwindow id=d33664e2562 href="http://www.ncbi.nlm.nih.gov/pubmed/29310963">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2565 href="https://doi.org/10.1016/j.ophtha.2017.11.017">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732438322">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d33664e2578 class=n-a></a>Sheppard JD, Toyos MM, Kempen JH, <i> et al.</i>: Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. <i>Invest Ophthalmol Vis Sci.</i> 2014; <b>55</b>(5): 29933002. <a target=xrefwindow id=d33664e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/24677110">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2592 href="https://doi.org/10.1167/iovs.13-12660">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2596 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4581692">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d33664e2605 class=n-a></a>Riordan-Eva P, Lightman S: Orbital floor steroid injections in the treatment of uveitis. <i>Eye (Lond).</i> 1994; <b>8</b>(Pt 1): 669. <a target=xrefwindow id=d33664e2613 href="http://www.ncbi.nlm.nih.gov/pubmed/8013721">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2616 href="https://doi.org/10.1038/eye.1994.12">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d33664e2626 class=n-a></a>Jennings T, Rusin MM, Tessler HH, <i> et al.</i>: Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema. <i>Jpn J Ophthalmol.</i> 1988; <b>32</b>(4): 38591. <a target=xrefwindow id=d33664e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/3236561">PubMed Abstract </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d33664e2646 class=n-a></a>Yoshikawa K, Kotake S, Ichiishi A, <i> et al.</i>: Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. <i>Jpn J Ophthalmol.</i> 1995; <b>39</b>: 716. <a target=xrefwindow id=d33664e2657 href="http://www.ncbi.nlm.nih.gov/pubmed/7643487">PubMed Abstract </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d33664e2666 class=n-a></a>Cunningham MA, Edelman JL, Kaushal S: Intravitreal steroids for macular edema: the past, the present, and the future. <i>Surv Ophthalmol.</i> 2008; <b>53</b>(2): 13949. <a target=xrefwindow id=d33664e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/18348879">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2677 href="https://doi.org/10.1016/j.survophthal.2007.12.005">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d33664e2686 class=n-a></a>Lowder C, Belfort R Jr, Lightman S, <i> et al.</i>: Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. <i>Arch Ophthalmol.</i> 2011; <b>129</b>(5): 54553. <a target=xrefwindow id=d33664e2697 href="http://www.ncbi.nlm.nih.gov/pubmed/21220619">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2700 href="https://doi.org/10.1001/archophthalmol.2010.339">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d33664e2709 class=n-a></a>Tsang AC, Virgili G, Abtahi M, <i> et al.</i>: Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Chronic Non-infectious Uveitis. <i>Ocul Immunol Inflamm.</i> 2017; <b>25</b>(5): 685692. <a target=xrefwindow id=d33664e2720 href="http://www.ncbi.nlm.nih.gov/pubmed/27191685">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2723 href="https://doi.org/10.3109/09273948.2016.1160130">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d33664e2732 class=n-a></a>Cao JH, Mulvahill M, Zhang L, <i> et al.</i>: Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. <i>Ophthalmology.</i> 2014; <b>121</b>(10): 18716. <a target=xrefwindow id=d33664e2743 href="http://www.ncbi.nlm.nih.gov/pubmed/24907061">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2746 href="https://doi.org/10.1016/j.ophtha.2014.04.012">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726703566"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2756 class=n-a></a>Fonollosa A, Lloren V, Artaraz J, <i> et al.</i>: Safety and Efficacy of Intravitreal Dexamethasone Implants in the Management of Macular Edema Secondary to Infectious Uveitis. <i>Retina.</i> 2016; <b>36</b>(9): 177885. <a target=xrefwindow id=d33664e2767 href="http://www.ncbi.nlm.nih.gov/pubmed/27183031">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2770 href="https://doi.org/10.1097/IAE.0000000000001001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726703566">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732230396"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e2783 class=n-a></a>Agarwal A, Handa S, Aggarwal K, <i> et al.</i>: The Role of Dexamethasone Implant in the Management of Tubercular Uveitis. <i>Ocul Immunol Inflamm.</i> 2018; <b>26</b>(6): 88492. <a target=xrefwindow id=d33664e2794 href="http://www.ncbi.nlm.nih.gov/pubmed/29190170">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2797 href="https://doi.org/10.1080/09273948.2017.1400074">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732230396">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d33664e2810 class=n-a></a>Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, <i> et al.</i>: The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. <i>Am J Ophthalmol.</i> 2010; <b>149</b>(4): 550561.e10. <a target=xrefwindow id=d33664e2821 href="http://www.ncbi.nlm.nih.gov/pubmed/20097325">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2824 href="https://doi.org/10.1016/j.ajo.2009.11.019">Publisher Full Text </a> | <a target=xrefwindow id=d33664e2828 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2975449">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d33664e2837 class=n-a></a>pSivida Corp: Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis. In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e2839 href="https://clinicaltrials.gov/ct2/show/NCT02746991">Reference Source</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d33664e2848 class=n-a></a>Jabs DA, Rosenbaum JT, Foster CS, <i> et al.</i>: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. <i>Am J Ophthalmol.</i> 2000; <b>130</b>(4): 492513. <a target=xrefwindow id=d33664e2859 href="http://www.ncbi.nlm.nih.gov/pubmed/11024423">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2862 href="https://doi.org/10.1016/s0002-9394(00)00659-0">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d33664e2871 class=n-a></a>Tranos PG, Wickremasinghe SS, Stangos NT, <i> et al.</i>: Macular edema. <i>Surv Ophthalmol.</i> 2004; <b>49</b>(5): 47090. <a target=xrefwindow id=d33664e2882 href="http://www.ncbi.nlm.nih.gov/pubmed/15325193">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2885 href="https://doi.org/10.1016/j.survophthal.2004.06.002">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d33664e2895 class=n-a></a>Pacheco PA, Taylor SR, Cuchacovich MT, <i> et al.</i>: Azathioprine in the management of autoimmune uveitis. <i>Ocul Immunol Inflamm.</i> 2008; <b>16</b>(4): 1615. <a target=xrefwindow id=d33664e2906 href="http://www.ncbi.nlm.nih.gov/pubmed/18716951">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2909 href="https://doi.org/10.1080/09273940802204519">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d33664e2918 class=n-a></a>Taylor SR, Habot-Wilner Z, Pacheco P, <i> et al.</i>: Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. <i>Ophthalmology.</i> 2009; <b>116</b>(4): 797801. <a target=xrefwindow id=d33664e2929 href="http://www.ncbi.nlm.nih.gov/pubmed/19344827">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2932 href="https://doi.org/10.1016/j.ophtha.2008.10.033">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d33664e2941 class=n-a></a>Taylor SR, Banker A, Schlaen A, <i> et al.</i>: Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. <i>Retina.</i> 2013; <b>33</b>(10): 214954. <a target=xrefwindow id=d33664e2952 href="http://www.ncbi.nlm.nih.gov/pubmed/23615343">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2955 href="https://doi.org/10.1097/IAE.0b013e31828ac07d">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d33664e2964 class=n-a></a>Imrie FR, Dick AD: Biologics in the treatment of uveitis. <i>Curr Opin Ophthalmol.</i> 2007; <b>18</b>(6): 4816. <a target=xrefwindow id=d33664e2972 href="http://www.ncbi.nlm.nih.gov/pubmed/18163000">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2975 href="https://doi.org/10.1097/ICU.0b013e3282f03d42">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d33664e2984 class=n-a></a>Doycheva D, Jgle H, Zierhut M, <i> et al.</i>: Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up. <i>Br J Ophthalmol.</i> 2014; <b>99</b>(1): 8791. <a target=xrefwindow id=d33664e2995 href="http://www.ncbi.nlm.nih.gov/pubmed/25061107">PubMed Abstract </a> | <a target=xrefwindow id=d33664e2998 href="https://doi.org/10.1136/bjophthalmol-2014-305535">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d33664e3007 class=n-a></a>Nussenblatt RB, Palestine AG, Chao CC, <i> et al.</i>: Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. <i>Am J Ophthalmol.</i> 1991; <b>112</b>(2): 13846. <a target=xrefwindow id=d33664e3018 href="http://www.ncbi.nlm.nih.gov/pubmed/1867297">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3021 href="https://doi.org/10.1016/s0002-9394(14)76692-9">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d33664e3031 class=n-a></a>Hogan AC, McAvoy CE, Dick AD, <i> et al.</i>: Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. <i>Ophthalmology.</i> 2007; <b>114</b>(5): 10006. <a target=xrefwindow id=d33664e3042 href="http://www.ncbi.nlm.nih.gov/pubmed/17467532">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3045 href="https://doi.org/10.1016/j.ophtha.2007.01.026">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d33664e3054 class=n-a></a>Nguyen QD, Ibrahim MA, Watters A, <i> et al.</i>: Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. <i>J Ophthalmic Inflamm Infect.</i> 2013; <b>3</b>(1): 32. <a target=xrefwindow id=d33664e3065 href="http://www.ncbi.nlm.nih.gov/pubmed/23514595">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3068 href="https://doi.org/10.1186/1869-5760-3-32">Publisher Full Text </a> | <a target=xrefwindow id=d33664e3072 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3610181">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726769785"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3081 class=n-a></a>Nguyen QD, Sadiq MA, Soliman MK, <i> et al.</i>: The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis). <i>Trans Am Ophthalmol Soc.</i> 2016; <b>114</b>: T3. <a target=xrefwindow id=d33664e3092 href="http://www.ncbi.nlm.nih.gov/pubmed/27630374">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3095 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5012855">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726769785">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d33664e3108 class=n-a></a>Buhaescu I, Izzedine H, Covic A: Sirolimus--challenging current perspectives. <i>Ther Drug Monit.</i> 2006; <b>28</b>(5): 57784. <a target=xrefwindow id=d33664e3116 href="http://www.ncbi.nlm.nih.gov/pubmed/17038868">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3119 href="https://doi.org/10.1097/01.ftd.0000245377.93401.39">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d33664e3128 class=n-a></a>Kempen JH, Daniel E, Gangaputra S, <i> et al.</i>: Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. <i>Ophthalmic Epidemiol.</i> 2008; <b>15</b>(1): 4755. <a target=xrefwindow id=d33664e3139 href="http://www.ncbi.nlm.nih.gov/pubmed/18300089">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3142 href="https://doi.org/10.1080/09286580701585892">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d33664e3151 class=n-a></a>Sharma SM, Nestel AR, Lee RW, <i> et al.</i>: Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. <i>Ocul Immunol Inflamm.</i> 2009; <b>17</b>(6): 40314. <a target=xrefwindow id=d33664e3162 href="http://www.ncbi.nlm.nih.gov/pubmed/20001261">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3165 href="https://doi.org/10.3109/09273940903072443">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/714947805"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3175 class=n-a></a>Daz-Llopis M, Salom D, Garcia-de-Vicua C, <i> et al.</i>: Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. <i>Ophthalmology.</i> 2012; <b>119</b>(8): 157581. <a target=xrefwindow id=d33664e3186 href="http://www.ncbi.nlm.nih.gov/pubmed/22525047">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3189 href="https://doi.org/10.1016/j.ophtha.2012.02.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/714947805">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d33664e3202 class=n-a></a>Schaap-Fogler M, Amer R, Friling R, <i> et al.</i>: Anti-TNF- agents for refractory cystoid macular edema associated with noninfectious uveitis. <i>Graefes Arch Clin Exp Ophthalmol.</i> 2014; <b>252</b>(4): 63340. <a target=xrefwindow id=d33664e3213 href="http://www.ncbi.nlm.nih.gov/pubmed/24366669">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3216 href="https://doi.org/10.1007/s00417-013-2552-8">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d33664e3225 class=n-a></a>Androudi S, Tsironi E, Kalogeropoulos C, <i> et al.</i>: Intravitreal adalimumab for refractory uveitis-related macular edema. <i>Ophthalmology.</i> 2010; <b>117</b>(8): 16126. <a target=xrefwindow id=d33664e3236 href="http://www.ncbi.nlm.nih.gov/pubmed/20378179">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3239 href="https://doi.org/10.1016/j.ophtha.2009.12.011">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d33664e3248 class=n-a></a>Farvardin M, Afarid M, Shahrzad S: Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. <i>J Ocul Pharmacol Ther.</i> 2012; <b>28</b>(6): 62831. <a target=xrefwindow id=d33664e3256 href="http://www.ncbi.nlm.nih.gov/pubmed/22794354">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3259 href="https://doi.org/10.1089/jop.2011.0199">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d33664e3268 class=n-a></a>Markomichelakis NN, Theodossiadis PG, Pantelia E, <i> et al.</i>: Infliximab for chronic cystoid macular edema associated with uveitis. <i>Am J Ophthalmol.</i> 2004; <b>138</b>(4): 64850. <a target=xrefwindow id=d33664e3279 href="http://www.ncbi.nlm.nih.gov/pubmed/15488796">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3282 href="https://doi.org/10.1016/j.ajo.2004.04.066">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d33664e3291 class=n-a></a>Miserocchi E, Modorati G, Pontikaki I, <i> et al.</i>: Golimumab treatment for complicated uveitis. <i>Clin Exp Rheumatol.</i> 2013; <b>31</b>(2): 3201. <a target=xrefwindow id=d33664e3302 href="http://www.ncbi.nlm.nih.gov/pubmed/23331715">PubMed Abstract </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718152028"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3312 class=n-a></a>Miserocchi E, Modorati G, Pontikaki I, <i> et al.</i>: Long-term treatment with golimumab for severe uveitis. <i>Ocul Immunol Inflamm.</i> 2014; <b>22</b>(2): 905. <a target=xrefwindow id=d33664e3323 href="http://www.ncbi.nlm.nih.gov/pubmed/24143896">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3326 href="https://doi.org/10.3109/09273948.2013.844265">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718152028">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732925659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3339 class=n-a></a>Constantin T, Foeldvari I, Anton J, <i> et al.</i>: Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(8): 11071117. <a target=xrefwindow id=d33664e3350 href="http://www.ncbi.nlm.nih.gov/pubmed/29592918">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3353 href="https://doi.org/10.1136/annrheumdis-2018-213131">Publisher Full Text </a> | <a target=xrefwindow id=d33664e3357 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6059050">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732925659">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726056513"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3370 class=n-a></a>Deuter CME, Zierhut M, Igney-Oertel A, <i> et al.</i>: Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. <i>Ocul Immunol Inflamm.</i> 2017; <b>25</b>(2): 21520. <a target=xrefwindow id=d33664e3381 href="http://www.ncbi.nlm.nih.gov/pubmed/26731514">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3384 href="https://doi.org/10.3109/09273948.2015.1099680">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726056513">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727623537"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3397 class=n-a></a>Mesquida M, Molins B, Lloren V, <i> et al.</i>: Twenty-Four Month Follow-Up of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema. <i>Retina.</i> 2018; <b>38</b>(7): 136170. <a target=xrefwindow id=d33664e3408 href="http://www.ncbi.nlm.nih.gov/pubmed/28520640">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3411 href="https://doi.org/10.1097/IAE.0000000000001690">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727623537">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d33664e3424 class=n-a></a>Davatchi F, Shams H, Rezaipoor M, <i> et al.</i>: Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). <i>Int J Rheum Dis.</i> 2010; <b>13</b>(3): 24652. <a target=xrefwindow id=d33664e3435 href="http://www.ncbi.nlm.nih.gov/pubmed/20704622">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3438 href="https://doi.org/10.1111/j.1756-185X.2010.01546.x">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725804496"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3447 class=n-a></a>Miserocchi E, Modorati G, Berchicci L, <i> et al.</i>: Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. <i>Br J Ophthalmol.</i> 2016; <b>100</b>(6): 7826. <a target=xrefwindow id=d33664e3458 href="http://www.ncbi.nlm.nih.gov/pubmed/26396026">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3461 href="https://doi.org/10.1136/bjophthalmol-2015-306790">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725804496">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d33664e3475 class=n-a></a>Tappeiner C, Miserocchi E, Bodaghi B, <i> et al.</i>: Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. <i>J Rheumatol.</i> 2015; <b>42</b>(4): 70611. <a target=xrefwindow id=d33664e3486 href="http://www.ncbi.nlm.nih.gov/pubmed/25641892">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3489 href="https://doi.org/10.3899/jrheum.140410">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d33664e3498 class=n-a></a>Elhai M, Deslandre CJ, Kahan A: Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian <i>et al</i>. <i>Arthritis Care Res (Hoboken).</i> 2011; <b>63</b>(2): 3078; author reply 308. <a target=xrefwindow id=d33664e3509 href="http://www.ncbi.nlm.nih.gov/pubmed/20890986">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3512 href="https://doi.org/10.1002/acr.20359">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d33664e3521 class=n-a></a>Kenawy N, Cleary G, Mewar D, <i> et al.</i>: Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. <i>Graefes Arch Clin Exp Ophthalmol.</i> 2011; <b>249</b>(2): 297300. <a target=xrefwindow id=d33664e3532 href="http://www.ncbi.nlm.nih.gov/pubmed/20922440">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3535 href="https://doi.org/10.1007/s00417-010-1523-6">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d33664e3544 class=n-a></a>Oregon Health and Science University: Abatacept in the Treatment of Uveitis. In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e3546 href="https://clinicaltrials.gov/ct2/show/results/NCT01279954">Reference Source</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732568394"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d33664e3555 class=n-a></a>Tugal-Tutkun I, Pavesio C, De Cordoue A, <i> et al.</i>: Use of Gevokizumab in Patients with Behet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study. <i>Ocul Immunol Inflamm.</i> 2018; <b>26</b>(7): 102333. <a target=xrefwindow id=d33664e3566 href="http://www.ncbi.nlm.nih.gov/pubmed/29370572">PubMed Abstract </a> | <a target=xrefwindow id=d33664e3569 href="https://doi.org/10.1080/09273948.2017.1421233">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732568394">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d33664e3582 class=n-a></a>National Eye Institute (NEI): Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e3584 href="https://clinicaltrials.gov/ct2/show/NCT02911116">Reference Source</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d33664e3594 class=n-a></a>Gilead Sciences: Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (Humboldt). In: ClinicalTrials.gov [cited 2019 Apr 27]. <a target=xrefwindow id=d33664e3596 href="https://clinicaltrials.gov/ct2/show/NCT03207815">Reference Source</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1413/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1413/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy<br/> <p> <div class=margin-bottom> Riccardo Sacconi <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Resources, Writing  Original Draft Preparation, Writing  Review & Editing </div> <div class=margin-bottom> Chiara Giuffr&egrave; <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Eleonora Corbelli <br/> <span>Roles: </span> Conceptualization, Data Curation, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Enrico Borrelli <br/> <span>Roles: </span> Data Curation, Methodology, Resources, Validation, Writing  Review & Editing </div> <div class=margin-bottom> Giuseppe Querques <br/> <span>Roles: </span> Conceptualization, Methodology, Resources, Validation, Writing  Review & Editing </div> <div class=margin-bottom> Francesco Bandello <br/> <span>Roles: </span> Conceptualization, Methodology, Resources, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1413/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 12 Aug 2019, 8:1413 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19198.1">https://doi.org/10.12688/f1000research.19198.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2019 Sacconi R <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21038 data-id=19198 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19198.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1413/v1/pdf?article_uuid=c54108b9-ee0c-4585-b5b0-59751df96f8b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19198.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Sacconi R, Giuffr C, Corbelli E <em>et al.</em> Emerging therapies in the management of macular edema: a review [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1413 (<a href="https://doi.org/10.12688/f1000research.19198.1" target=_blank>https://doi.org/10.12688/f1000research.19198.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19198 id=mobile-track-article-signin-19198 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19198?target=/articles/8-1413/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21038 /> <input name=articleId type=hidden value=19198 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Andrew Chang</strong>, Sydney Institute of Vision Science, Australia; Save Sight Institute, University of Sydney, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Akitaka Tsujikawa</strong>, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Japan </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 12 Aug 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1413/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1413/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=54919-51943></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=54920-51942></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1413/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>12 Aug 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andrew Chang</strong>, Sydney Institute of Vision Science, Australia; Save Sight Institute, University of Sydney, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Akitaka Tsujikawa</strong>, Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Japan </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1413/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1413/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging therapies in the management of macular...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1413/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1413/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1413/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Sacconi R et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1413/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1413",
            templates : {
                twitter : "Emerging therapies in the management of macular edema: a review. Sacconi R et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1413/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging therapies in the management of macular edema: a review", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging therapies in the management of macular edema: a review", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19198/21038")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21038");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "48800": 0,
                           "48128": 0,
                           "48129": 0,
                           "48130": 0,
                           "51942": 0,
                           "51943": 1,
                           "48796": 0,
                           "48797": 0,
                           "48798": 0,
                           "48126": 0,
                           "48799": 0,
                           "48127": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "5640d71c-a442-4afa-84cf-c868de51ea9b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1413.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1413.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1413.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1413.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1413.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>